A recent study reveals that individuals who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end conventional lifestyle regimens.
Published data in a prominent medical journal points out that while obese people frequently drop a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying these treatments must be aware of the risk of quick rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight in about 18 months.
Comparing Treatments
The analysis, which looked at dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with other pills.
The team point out that individuals who shed pounds through lifestyle changes alone generally see a more gradual creep back—approximately 100 grams monthly—after stopping.
The Reason for the Rapid Rebound
Nutrition scientists suggest the way of the injections is key to understanding the accelerated regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating far more likely."
A Chronic Issue?
The NHS recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, given the significant potential of weight regain, the therapy should be considered ongoing.
This view is reinforced by pharmaceutical companies, who say that the results "highlight the long-term character of obesity," comparing it to managing conditions like diabetes.
User Experiences
Users who have come off the jabs report a intense return of appetite.
"I experienced a switch activating and you become extremely hungry," recalled one woman.
This difficulty is compounded if individuals have not developed sustainable lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is more common among women than men.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, researchers caution that while these medications are powerful agents for weight loss, they are not a standalone solution and lasting health benefits hinges on ongoing lifestyle management.
